Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2021 / Articles / Jun / Celebration of Design
Business & Regulation Business Practice

Celebration of Design

Sustainable machinery wins iF Design Award

By Maryam Mahdi 06/04/2021 1 min read

Share

ACG has won an iF Design Award for its latest packaging machine, Karton X. The machine was developed to pack blisters, bottles, tubes, vials, and ampoules in secondary packaging, but also touts features that contribute to sustainability. ACG’s Managing Director, Karan Singh, explains what the award represents for them and how the industry can become greener.

The iF Design Award is coveted in the industry for excellence in design! Karton X, which belongs to our NXT range of machines, reflects our philosophy of designing and manufacturing high-quality, reliable machines. The design was inspired by the aesthetic design of stealth fighter-bomber crafts incorporating ergonomic handling with an intelligent human-machine interface. It was developed using recyclable and easy-to-clean materials.

We have followed three key initiatives to make our plants more sustainable and reduce their carbon footprint. For example, for the last several years, we have deployed technology to understand what is wasted in the manufacturing processes. AI and the Internet of Things have enabled us to make manufacturing contained, continuous, and connected. This has significantly optimized raw material use, reduced lag time, and enabled us to develop final products with fewer defects.

We have also invested in solar farms that harness renewable energy to operate some of our manufacturing plants and offices. And we constantly work toward environmental protection. An example of this is the way we use water in our facilities. For the 99 percent of water our plants receive, one percent goes through our Zero Liquid Discharge (ZLD) set up that treats effluents before release – preventing any potential harm to the environment. We use an engineering approach to water treatment at our ZLD plant, where all water is recovered, and contaminants are reduced to miniscule solid waste, which are not discharged in the environment.

The reality of climate change is hard to ignore. We are also faced with the fact that the Earth’s natural reserves and resources are limited. At the current rate of consumption, we will require 50 percent more food, 45 percent more energy, and 30 percent more water in the next two decades. To avoid rapidly depleting the Earth’s resources, we must manufacture responsibly and reduce consumption.

Environmental sustainability is, however, a growing concern in most manufacturing industries, and we in the pharma industry are no exception. There is an increasing need to design facilities that conserve and optimize the use of resources – energy, water, and raw materials – while reducing waste.

I also encourage companies to address environmental, social, and governance aspects in a strategic and integrated manner, rather than undertaking ad hoc initiatives. Continuing their focus on increasing competitiveness and revenues, companies can manufacture and function with a responsible approach to the environment and natural resources. The current COVID-19 scenario gives us an opportunity to go well beyond compliance and make ourselves truly ready for the future.

It’s encouraging to see that, despite barriers such as costs and regulation, many pharma manufacturers are already switching to both sustainable and advanced manufacturing methodologies. But it’s important for us all to keep in mind that tackling climate emergencies will require global cooperation between companies and stakeholders. Together, we should act on an environmentally sustainable economic model to deliver global health, taking integrated action to protect and support people and our planet.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.